Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B

The Hepatitis B Research Network Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B (HBRN Immune Tolerant A) study sought to determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B “e” antigen (HBeAg) positive adults who were in the immune tolerant phase. Additionally, the study evaluated the safety and sustained responses after treatment with entecavir and peginterferon alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults in the immune tolerant phase.

乙型肝炎研究网络（Hepatitis B Research Network, HBRN）开展的「恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎乙肝e抗原（Hepatitis B e-antigen, HBeAg）阳性免疫耐受成人」研究（HBRN免疫耐受队列A，HBRN Immune Tolerant A），旨在探究先予8周恩替卡韦单药治疗、后续联合40周恩替卡韦与聚乙二醇干扰素的联合治疗方案，针对免疫耐受期乙肝e抗原阳性慢性乙型肝炎成人患者的临床疗效。此外，本研究同时评估了恩替卡韦联合聚乙二醇干扰素α-2a治疗免疫耐受期乙肝e抗原阳性慢性乙型肝炎成人患者的安全性及治疗后持续应答情况。